Levodopa dry powder inhalation - PureIMS
Alternative Names: Levodopa Cyclops™; Levodopa dry powder inhalationLatest Information Update: 12 Feb 2024
Price :
$50 *
At a glance
- Originator PureIMS
- Class Antiasthmatics; Antiparkinsonians; Catecholamines; Small molecules
- Mechanism of Action Dopamine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Parkinson's disease
Most Recent Events
- 12 Feb 2024 Levodopa dry powder inhalation is available for licensing in USA, European Union as of 18 Jan 2024
- 18 Jan 2024 PureIMS announces intention to submit regulatory application for abbreviated registration for Parkinson's disease
- 18 Jan 2024 Pharmacokinetics and adverse events data from a phase I trial in Parkinson's disease released by PureIMS